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Exon-centric regulation of 
ATM expression is population-
dependent and amenable to 
antisense modification by 
pseudoexon targeting
Jana Kralovicova1, Marcin Knut1, Nicholas C. P. Cross1,2 & Igor Vorechovsky1
ATM is an important cancer susceptibility gene that encodes a critical apical kinase of the DNA damage 
response (DDR) pathway. We show that a key nonsense-mediated RNA decay switch exon (NSE) in ATM 
is repressed by U2AF, PUF60 and hnRNPA1. The NSE activation was haplotype-specific and was most 
promoted by cytosine at rs609261 in the NSE 3′ splice-site (3′ss), which is predominant in high cancer 
risk populations. NSE levels were deregulated in leukemias and were influenced by the identity of 
U2AF35 residue 34. We also identify splice-switching oligonucleotides (SSOs) that exploit competition 
of adjacent pseudoexons to modulate NSE levels. The U2AF-regulated exon usage in the ATM signalling 
pathway was centred on the MRN/ATM-CHEK2-CDC25-cdc2/cyclin-B axis and preferentially involved 
transcripts implicated in cancer-associated gene fusions and chromosomal translocations. These results 
reveal important links between 3′ss control and ATM-dependent responses to double-strand DNA 
breaks, demonstrate functional plasticity of intronic variants and illustrate versatility of intronic SSOs 
that target pseudo-3′ss to modify gene expression.
Introns are removed by a large and highly dynamic RNA-protein complex termed the spliceosome, which orches-
trates complex interactions between primary transcripts, small nuclear RNAs (snRNAs) and a large number of 
proteins1. Spliceosomes assemble ad hoc on each intron in an ordered manner, starting with recognition of the 5‘ 
splice site (5’ss) by U1 snRNA or the 3′ ss by the U2 pathway1,2, which involves binding of the U2 auxiliary factor 
(U2AF) to the 3′ ss region to facilitate U2 recognition of the branch point sequence (BPS)3. U2AF is a stable het-
erodimer composed of a U2AF2-encoded 65-kD subunit (U2AF65), which binds the polypyrimidine tract (PPT), 
and a U2AF1-encoded 35-kD subunit (U2AF35), which interacts with highly conserved AG dinucleotides at 3′ ss 
and stabilizes U2AF65 binding4. In addition to the BPS/PPT unit and 3′ ss/5′ ss, accurate splicing requires auxil-
iary sequences or structures that activate or repress splice site recognition, known as intronic or exonic splicing 
enhancers or silencers. These elements allow genuine splice sites to be recognized among a vast excess of cryptic 
or pseudo-sites in the genome of higher eukaryotes, which have similar sequences but outnumber authentic 
sites by an order of magnitude5. Although they often have a regulatory function6, molecular mechanisms of their 
repression are poorly understood.
Exome sequencing studies have revealed a restricted pattern of somatic mutations in U2AF1/U2AF2 and other 
genes involved in 3′ ss recognition in cancer cells, including SF3B1, ZRSR2, SF1, SF3A1, PRPF40B, and SRSF2 
(reviewed in7). These genes encode products that often interact during spliceosome assembly8–10 and exhibit a 
high degree of mutual exclusivity of cancer-associated mutations7, pointing to the existence of a shared oncogenic 
pathway. Transcriptome profiling in leukemias carrying these mutations detected numerous alterations in splicing 
of mRNA precursors7, but key links between specific RNA processing defects and cancer initiation or progression 
have remained obscure, despite the great promise of these targets for therapeutic modulation. In addition, it has 
been unclear why the highly restricted mutation pattern in these cells has not been associated with a limited and 
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clearly defined set of RNA processing defects with oncogenic properties. Furthermore, exon usage in DDR genes, 
critical players in malignant transformation, has not been fully characterized in cells lacking 3′ ss processing factors 
and natural DNA variants that influence their activation have been unknown.
Here, we identify a U2AF-repressed nonsense-mediated decay (NMD) switch exon in ATM 
(ataxia-telangiectasia, A-T, mutated). We show that the extent to which this event limits ATM expression depends 
largely on a common intronic variant rs609261 located in the NSE 3′ ss. By exploiting novel intronic cis-elements 
that control NSE inclusion levels, we identify SSOs that modulate NSE activation by targeting a competing pseudo-
exon in the same intron. In addition, we identify U2AF-related proteins that control NSE selection. Using RNA-Seq, 
we also show that the U2AF-mediated regulation of DDR pathways is centred on the ATM-CHEK2-CDC25-cdc2/
cyclin-B axis, suggesting that it has coevolved with cellular responses to double-strand DNA breaks (DSBs). Finally, 
we demonstrate a preferential involvement of U2AF-regulated transcripts in cancer-associated gene fusions and 
chromosome translocations.
Results
Identification of a U2AF-repressed cryptic exon in ATM. We and others have recently shown that 
depletion of each U2AF subunit resulted in down- and up-regulation of a large number of exons that were 
predominantly alternatively spliced11,12. When inspecting global RNA processing changes in cells depleted of 
U2AF35, we found an unexpectedly strong activation of a cryptic, 29-nt ATM exon that was not annotated by 
RefSeq (termed NSE for NMD switch exon, Fig. 1a). The NSE activation was observed also in cells individually 
depleted of each U2AF35 isoform with isoform-specific small interfering RNAs (siRNAs) and with SSOs targeting 
3′ ss of alternatively spliced U2AF1 exons Ab and 3, which encode isoform U2AF35b and U2AF35a, respectively 
Figure 1. Identification of a U2AF-repressed cryptic exon in ATM intron 28. (a) Schematics of NSE 
activation. NSE sequence (upper panel) is boxed, asterisk denotes rs609261, black rectangles show the indicated 
antisense oligonucleotides. Genome browser views of RNA-Seq data from RNAi- or SSO-mediated depletions of 
both U2AF35 isoforms (ab-), U2AF35a (a-), U2AF35b (b-) and controls (c) are shown in the lower panel. SSOs 
targeting 3′ ss of U2AF1 exons Ab and 3 and U2AF35 siRNAs were as described11. Y axis, read densities. NSE 
inclusion/exclusion is schematically shown by dotted lines at the top. ATM exons (gray boxes) are numbered as 
in ref. 13. The 29-nt NSE introduced a stop codon in the ATM mRNA. (b) Validation of the NSE activation by 
RT-PCR (upper panel) in independent depletions (lower panel). RT-PCR primers (ATM-F, ATM-R, Table S1) 
are denoted by arrows in panel a. Spliced products are shown to the right, the percentage of transcripts with 
NSE is at the top. Error bars denote SDs of two transfections experiments. ***p < 0.0001, **p < 0.001. (c) NSE 
inclusion in mature transcripts inversely correlates with residual U2AF. r, Pearson correlation. Estimates of 
heterodimer levels were as described11.
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(Fig. 1a). Validation of RNA-Seq data using RT-PCR showed that NSE was present in ~10-20% of polyadenylated 
transcripts in untreated human embryonic kidney (HEK) 293 cells, similar to levels observed in lymphoblastoid 
cell lines13. The NSE inclusion levels increased to ~75% in cultures depleted of ~90% U2AF35 and to ~50% in 
cells depleted of ~75% U2AF65 (Fig. 1b), were siRNA dose-dependent and inversely correlated with the estimated 
amount of available U2AF heterodimers (Fig. 1c), consistent with the requirement of each U2AF subunit for 
NSE repression. RNA-Seq data also revealed retention of intronic sequences surrounding NSE (Fig. 1a) but not 
adjacent introns, suggesting that intron 28 is ‘detained’ and could be spliced post-transcriptionally14. Retention 
levels of intron 28 were affected neither by SSO- nor siRNA-mediated depletion of U2AF35 (Fig. 1a) and no 
other cryptic exon in this gene was activated to the same extent as NSE. Thus, NSE plays an important role in the 
exon-centric regulation of ATM expression by U2AF.
NSE activation and ATM expression is modified by rs609261. Examination of genomic sequences 
surrounding NSE revealed that position -3 relative to the NSE 3′ ss is polymorphic at rs609261 where thymine 
(T) is predominant in African and Asian populations and cytosine (C) in Caucasians (Fig. 2a). The base identity 
at this position is critical for universal exon recognition, with a CAG>TAG>AAG>GAG hierarchy of exon 
inclusion levels at the 3′ ss consensus15. To confirm that the NSE usage is allele-specific, we examined splicing of 
two reporter constructs that contained C or T at this position following transient transfections into HEK293 cells 
(Fig. 2b). As expected, the T construct yielded lower NSE inclusion than the C reporter, both in untreated cells 
and cells individually depleted of each U2AF subunit (Fig. 2c).
To test whether the allele-specific NSE usage results in differential protein expression in cells lacking U2AF35, 
we first sequenced DNA from available cell lines across rs609261 to obtain transfectable cells homozygous for 
each allele. We found that HEK293 cells were homozygous for the C allele and HeLa cells were homozygous for 
the T allele (Fig. 2d). Immunoblots from the U2AF35-depleted cells and untreated controls confirmed efficient 
depletion in each cell line and a greater U2AF-mediated decline of ATM expression in the presence of the C allele 
than the T allele (Fig. 2e,f and Fig. S1a–c). Depletion of UPF1, a key component of the NMD pathway, revealed a 
dose-dependent increase of NSE inclusion in ATM mRNAs (Fig. 2g). No signal from a putative truncated ATM 
was detected on immunoblots from depleted cells.
Because U2AF-repressed and -activated exons show preferential responses to U2AF-related proteins11, we 
depleted HEK293 cells of PUF60 and CAPERα , and also several heterogeneous nuclear ribonucleoproteins, 
including hnRNP A1. PUF60 interacts with uridine-rich motifs at 3′ ss16 and hnRNP A1 forms a ternary complex 
with U2AF on AG-containing U-rich RNAs17. Depletion of either PUF60 or hnRNP A1 increased NSE inclusion 
(Fig. 2h) while PUF60 overexpression led to NSE skipping (Fig. 2i). Together, these results show that the rs609261- 
and population-dependent NSE activation deep in ATM intron 28 is regulated by U2AF, PUF60 and hnRNP A1 
and demonstrate that functionality of a common intronic polymorphism varies with cellular levels of RNA-binding 
proteins that facilitate 3′ ss recognition.
NSE inhibition by SSOs promotes ATM expression. To test if NSE activation in cells lacking U2AF can 
be repressed to restore ATM expression, we first individually cotransfected the C-allele reporter construct with 
SSOs targeting NSE splice sites (Fig. 1a). SSOs were modified with phosphorothioate linkages at each end and 
with 2′-O-methyl at each ribose and were designed to avoid the PPT of NSE, stable Mfold-predicted stems and 
rs609261. Each SSO diminished NSE inclusion in a dose-dependent manner both in exogeneous (Fig. 3a) and 
endogeneous (Fig. 3b) transcripts and the SSO targeting the NSE 3′ ss was more efficient than the SSO bridging 
its 5’ss at the same concentrations.
We next examined if the NSE 3′ ss SSO can increase ATM protein expression. The reduced ATM expression in 
cells lacking U2AF35 was partially rescued by this SSO in HEK293 cells but this was not apparent in HeLa cells 
where the NSE activation and reconstitution was less efficient at the same SSO concentrations (Fig. S1a and S1b, 
lanes 5–8 vs 9–12; Fig. S1c). We also tested if the SSO NSE3 can influence downstream ATM targets in HEK293 
cells exposed to ionizing radiation (IR). The low ATM expression in cells lacking U2AF35 was partially rescued 
by this SSO also in IR-exposed cells (Fig. 3c, lanes 1 vs 2 and 5 vs 6, and Fig. S1e, lanes 5–8 vs 9–12). Following 
IR, activated ATM autophosphorylated at S198118 was reduced in depleted cells as compared to untreated cells 
(Fig. S1e, lanes 1–4 vs 5–8 and Fig. 3c, lane 6 vs 8) and this signal also appeared slightly increased following expo-
sure to the NSE 3′ ss SSO (Fig. S1e, lanes 5–8 vs 9–12, and Fig. 3c, lane 5 vs 6). We also overexpressed wild-type 
CHEK2 in (mock)-irradiated cells (mock)-depleted of U2AF, a serine/threonine kinase phosphorylated by ATM 
at T68 in response to DSBs19. Cells lacking U2AF had markedly lower levels of endogenous CHEK2 compared to 
controls, which did not appear to be altered by the NSE 3′ ss SSO (Fig. S1e, lanes 1–12). In contrast, exogeneous 
CHEK2 was increased in depleted cells both in IR-exposed and -unexposed cells (lanes 1–4 vs 5–8, see also Fig. 
S1f,g further below).
Taken together, NSE activation was efficiently inhibited by SSOs that block access to NSE splice sites and do 
not support RNase H cleavage. The more efficient SSO partially rescued the NSE-mediated inhibition of ATM.
NSE activation is regulated by a downstream pseudoexon. To identify intronic regulatory 
cis-elements that control NSE inclusion in mature transcripts, we took advantage of a previously reported A-T 
mutation IVS28-159A > G13. We noticed that this mutation activated the NSE 3′ ss while repressing its 5’ss and 
promoting a downstream 5’ss instead, introducing a 112-nt cryptic exon in the mRNA13. We also noticed that 
within this exon, there was a strong 3′ ss consensus preceded by optimal BPS/PPT motifs, which may bind U2AF 
and activate a smaller, 24-nt pseudoexon (termed PE; Fig. 4a). Examination of published RNA crosslinking/
immunoprecipitation data20 in ATM showed U2AF65 binding upstream and downstream of NSE and upstream 
of PE, suggesting that NSE activation may be controlled by competition between partially productive splice-
osomes assembled at the PE 3′ ss and the NSE 3′ ss. The two 3′ ss are conserved in mammals and are separated 
www.nature.com/scientificreports/
4Scientific RepoRts | 6:18741 | DOI: 10.1038/srep18741
by a distance smaller than the minimal intron size, sterically preventing simultaneous recognition of NSE and 
PE (Fig. 4a). Deletion of the PE PPT/3′ ss introduced in the C minigene, which should alleviate NSE repression 
through diminished U2AF binding to PE, increased NSE inclusion (Fig. 4b), in agreement with the 3′ ss competi-
tion. This deletion also induced retention of the intron that separates NSE and PE, mimicking the splicing pattern 
of the A-T mutation IVS28-159A > G. Increasing the intron length from 59 to 79 nt, thereby overcoming a steric 
Figure 2. NSE activation and ATM expression are modified by rs609261. (a) Allelic frequencies at rs609261 
in the indicated populations66. (b) Minigene schematics. An XhoI/XbaI segment of ATM containing NSE 
and exon 29 was cloned between U2AF1 exons 2 and 4 (black boxes). RT-PCR primers to amplify exogenous 
transcripts (PL3 and ATM-R, Table S1) are denoted by arrows. (c) The rs609261-dependent NSE activation in 
exogenous pre-mRNAs. HEK293 cells depleted of U2AF35 or U2AF65 were transiently transfected with  
T (black) and C (gray) minigenes. Final concentration of the U2AF35 and U2AF65 siRNAs was 30 and  
60 nM, respectively. (d) Identification of cell lines homozygous at rs609261 (asterisk). NSE is boxed. (e,f)  
Allele-specific activation of NSE in endogenous transcripts limits ATM expression in a dose-dependent manner. 
The source of endogenous transcripts is at the bottom, antibodies are to the right. Concentration of siRNAs  
in HEK293 cultures was 3, 10 and 30 nM. Concentration of siRNAs in HeLa cultures was 6.6, 20 and 60 nM. C1, 
C2, control siRNAs. Transfection efficiency was monitored by a GFP-plasmid and fluorescent microscopy.  
(g) UPF1 depletion increased NSE activation (upper panel) and upregulated isoform U2AF1c (lower panel). The 
U2AF1c isoform contains both exons Ab and 3 and is repressed by NMD11,67. Final concentration of the UPF1 
siRNA was 7, 20 and 60 nM. SC, a scrambled control. Error bars are SDs of independent transfections. (h) NSE 
inclusion levels in cells depleted of U2AF-related proteins and a subset of heterogenous nuclear RNPs. Error 
bars denote SDs of two transfections. Immunoblots are shown to the right. Final concentration of the U2AF35 
siRNA was 25 nM; the remaining siRNAs were at 60 nM. C, controls. (i) Overexpression of PUF60 induced NSE 
skipping. Immunoblots are shown below, antibodies to the right.
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hindrance imposed by the insufficient distance between the two pseudo-3′ ss, also improved NSE inclusion and 
diminished the intron retention (Fig. 4b).
To test if NSE can influence PE inclusion in the mRNA, we first eliminated the NSE 3′ ss. The NSE 3′ ss mutation 
activated a cryptic 3′ ss 7-nt downstream, which had a diminished requirement for U2AF (Fig. 4c, lanes 1, 2 and 6, 
7, Table S2). Because extending the intron between NSE and PE on this background also failed to activate PE (lanes 
3 and 8) and because PE lacks exonic splicing enhancers and has a suboptimal BPS (Table S3), we inserted a 24-nt 
stemloop derived from a mammalian-wide interspersed repeat (MIR) in the middle of PE. This MIR hairpin acts as 
a nearly universal exon definition module through an exposed splicing enhancer in a terminal RNA triloop21. The 
enlarged PE was strongly activated in mock-depleted cells, but was outcompeted by NSE in cells lacking U2AF35 
(lanes 4 and 9), demonstrating differential requirements of the two pseudoexons for U2AF(35). The construct 
Figure 3. Rescue of U2AF-repressed ATM expression by SSOs targeting NSE. (a,b) Efficient SSO-mediated 
NSE inhibition in exogeneous (a) and endogenous (b) ATM transcripts. Mean NSE inclusion levels of two 
transfection experiments are shown in the right panels. (c) Restoration of ATM protein levels by SSOs that 
blocks access to NSE. Cells lacking U2AF35 and control cells were transfected with the SSO targeting the NSE 
3’ss and a control SSOs (Fig. 1a and Table S1), as described61,68. After 48 hrs, the cells were exposed to ionizing 
radiation (IR, 10 Gy) and harvested 1 hr later. Cell lysates were separated using a gradient SDS-PAGE. Western 
blotting was with antibodies shown to the right. (d) SSO-NSE3-mediated enhancement of ATM protein in 
cell lines homozygous at rs609261. Columns represent the average fold difference in ATM expression between 
SSO-NSE3-treated and SSO-C-treated homozygous cells depleted of U2AF35. Error bars represent SD of two 
biological replicates. P-values comparing SSO-C with SSO-NSE3-treated counterparts are shown at the top. 
Representative immunoblots are in Fig. S1a,b.
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containing both the MIR insertion in PE and the extended intron finally generated mRNAs containing both NSE 
and PE (lanes 5 and 10).
Intronic SSOs targeting competing pseudoexons to modulate gene expression. Next, we 
employed this MIR reporter to test the impact of NSE and PE SSOs on exon usage and ATM expression. Figure 4d 
shows that the NSE 3′ ss SSO repressed transcripts containing NSE and upregulated those with PE whereas the 
opposite effect was found for SSOs targeting the MIR enhancer loop in PE. We observed the same pattern for the 
reporter in which NSE and PE were separated by a distance insufficient for their simultaneous inclusion in the 
Figure 4. Identification of intronic cis-elements and SSOs that modulate NSE activation. (a) Schematics 
of two pseudoexons in ATM intron 28. Canonical exons, NSE and PE are shown as gray, white and checkered 
boxes, respectively. Asterisk indicates location of the IVS28-159A > G substitution13. In this A-T case, both 
NSE and PE were included in the ATM mRNA together with the intervening sequence. Canonical and aberrant 
transcripts are denoted by dotted lines above and below the pre-mRNA. Middle panel shows RNA-Seq read 
densities for NSE in cells depleted of both U2AF35 isoforms (ab-) together with U2AF65 tags/high-confidence 
binding sites (horizontal lines/rectangles) identified by crosslinking and immunoprecipitation20. The 100 
basewise vertebrate conservation by Phylop (100 VC) is at the bottom. The lower panel shows mutations  
(in red and underlined) introduced in the C-minigene. (b) Splicing pattern of wildtype and mutated C 
minigenes. Mutations are at the bottom of panel (a); RNA products are shown schematically to the right. The 
largest product produced by clone PE delPPT/AG includes the shortened pseudointron. (c) Splicing pattern 
of C minigenes mutated in NSE (lanes 2, 3, 7 and 8) or PE (lanes 4, 5, 9 and 10) in (mock)-depleted HEK293 
cells. Mutations are at the bottom; their sequences are in Table S2. Spliced products are schematically shown 
to the right. A hairpin symbol above PE denotes the MIR stem-loop insertion; cr3’ss, a cryptic 3’ss activation 
7 nt downstream of the authentic NSE 3’ss. (d,e) SSO-induced pseudoexon switching. Transfected minigenes 
are shown at the top, spliced products to the right and SSOs at the bottom. SSO sequences are in Table S1. Final 
concentration of SSOs shown in panels (d–g) was 3, 10 and 30 nM. (f) PE SSOs induced NSE skipping.  
(g) SSOs targeting a sequence that activates NSE upon deletion (PEdelPPT/AG; panel a and b) inhibit PE. 
(h) NSE activation is haplotype-dependent. Minigene haplotypes at the indicated variants are at the bottom. 
Columns represent mean NSE inclusion, error bars are SDs, asterisks denote statistically significant differences 
as in Fig. 1b.
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mRNA (Fig. 4e). These results suggested that SSOs targeting PE and/or U2AF65 binding sites upstream of PE 
may potentially promote NSE inclusion and reduce ATM expression, cancelling out the NSE SSOs. This approach 
could provide a broader strategy for intronic SSOs to modulate gene expression in either direction by target-
ing competing pseudoexons, one of which is critical for gene regulation. To test this concept, we examined PE 
SSOs. Although SSOs targeting PE splice sites induced NSE skipping in exogeneous and endogeneous transcripts 
(Fig. 4f), SSOs blocking access to U2AF65 binding sites just upstream of PE (Fig. 4a), ie. to the NSE-repressing 
motif identified in construct delPPT/AG (Fig. 4b), reduced PE inclusion and slightly increased NSE in the MIR 
reporter (Fig. 4g). A longer oligo extending in the 5’ direction (SSO-PEBP, Table S1) did not alter NSE inclusion 
levels.
PE contains a natural G/A variant rs4988000, which may also influence NSE recognition (Fig. 4h). Transfections 
of C and T minigenes systematically mutated at rs4988000 revealed that the rare A allele at rs4988000 decreased 
NSE inclusion on each pre-mRNA, both in U2AF35- and mock-depleted cells. Thus, the highest NSE inclusion 
was produced by the most frequent haplotype in Caucasians (CG), followed by haplotypes CA > TG > TA.
Taken together, the haplotype-dependent activation of the U2AF-repressed NSE can be modified by SSOs that 
target splicing regulatory motifs of competing pseudo-3′ ss.
Regulation of ATM signalling by U2AF: DSBs at the focal point. Because ATM is a key apical kinase 
in the DDR pathway22 and NMD switch exons altered by U2AF were frequent in genes encoding U2AF protein 
interaction partners11, we systematically characterized U2AF(35)-induced RNA processing changes of currently 
known ATM substrates23 and other constituents of the ATM signalling network24. Interestingly, although genes 
involved in the DDR and cell cycle control that contained U2AF(35)-dependent exons were only marginally 
enriched (FDR = 0.08)11, each component in the ATM-CHEK2-CDC25-CDC2/cyclin B axis showed RNA pro-
cessing alterations (Fig. 5a, Fig. S2). This pathway is critical for ATM signalling of DSBs22.
First, reduced ATM expression in cells lacking U2AF (Fig. S1e) was associated with decreased CHEK2 mRNA, 
increased retention of CHEK2 intron 10, and skipping of exons 9 and 11 (Fig. 5a). RNA processing alterations of 
known CHEK2 substrates were limited to genes regulating the cell cycle (CDC25A, CDC25B, CDC25C and TTK; 
Fig. 5a, S3a,b, S4a) and were not apparent in genes involved in DNA repair (BRCA1/2, XRCC1, FOXM1, TRIM28) 
or p53 signalling (TP53, MDM4, CABIN1, STRAP, AATF). CHEK2 exon 9 skipping, which is predicted to activate 
NMD, was only marginally increased 24 hrs after IR and did not appear to contribute to the decline of total CHEK2 
observed as early as 30 min after IR (Fig. 5b,c). As CHEK2 exon 9 inclusion was increased only for the highest 
concentration of tested UPF1 siRNAs (Fig. 5d), we transfected HEK293 cells with an SSO targeting its 3′ ss. This 
treatment induced exon 9 skipping and reduced expression of the CHEK2 protein (Fig. 5e). SSOs targeting NSE or 
PE did not have any effect on CHEK2 exon 9 inclusion (Fig. 5f). Skipping of exon 9, but not NSE, was dramatically 
increased in cells lacking SF3B1 (Fig. 5g). To address why exogenous expression of CHEK2 was elevated in cells 
lacking U2AF35 as compared to controls (Fig. S1e), we cotransfected HEK293 cells with the CHEK2-repressing 
SSO and a CHEK2-expressing plasmid (Fig. S1f,g). Reduced endogenous CHEK2 was associated with a significant 
increase of exogenous CHEK2 also in U2AF-proficient cells, pointing to a tight homeostatic regulation of the total 
CHEK2 protein in the cell.
Second, U2AF was required for full activation of CDC25A exon 6 (Fig. 5a), which encodes a serine residue 
(S178) phosphorylated by CHEK2/CHEK1. U2AF(35) was also required for inclusion of exon 3 of CDC25B and 
CDC25C (Fig. S3a,b), confirming microarray data25. CDC25B exon 3 encodes multiple phosphorylated residues, 
including S169; the isoform phosphorylated at S169 localizes to the centrosomes and accumulates during mito-
sis26. CDC25C exon 3 encodes T67 phosphorylated by cdc2/cyclin-B as a part of the autoamplification loop27. 
Phosphorylated T67 in CDC25C creates a binding site recognized by the WW domain of PIN127, which sustained 
activation of another U2AF-repressed NMD switch exon (Fig. S4b), possibly modifying catalytic activity of this 
abundant peptidyl-prolyl isomerase. Finally, cyclin B1 and B2 mRNAs were upregulated in cells lacking U2AF35 
as well as cyclin B1-interacting protein (CCNB1IP1), although their RNA processing patterns did not appear 
altered (Fig. 5a). Cyclin B upregulation was associated with a detained CDK1 intron (Fig. S4c), which may be 
spliced post-transcriptionally14.
ATM recruitment to DSB is facilitated by the MRN complex, consisting of MRE11, RAD50 and NBN22. NBN 
showed no obvious RNA processing changes in cells lacking U2AF35, but RAD50 mRNA was downregulated, 
possibly through activation of a NMD switch exon and/or additional splicing alterations (Fig. S5a-c and Fig. S2). 
The last MRE11A exon was upregulated, possibly as a result of a promotion of distal alternative polyadenylation 
site in depleted cells, which is used in most cell types, but not in B cells28. DEXSeq analysis did not detect signif-
icant RNA processing changes in transcripts encoding other members of the phosphatidylinositol 3 kinase-like 
family of serine/threonine kinases (ATR and PRKDC), nor in BRCA1/2, RNF168 and the ATM interactor ATMIN. 
Additional ATM interacting partners with altered exon or gene expression included RPS6, SRSF1 and other SR 
proteins, EP300, RPA2, BLM, FANCD2 and FANCI, PPP2R5C and PPP2R5D, and SMC3, a central component of 
the cohesin complex (Fig. S2).
Depletion of U2AF35 was associated with preferential alterations of genes/exons involved in chromatin modi-
fication11, which have numerous functional links to ATM signalling (Fig. S2)22. For example, the INO80 chromatin 
remodelling complex is phosphorylated by ATM and is functionally linked to checkpoint regulators, including 
CHEK229. U2AF inhibited INO80C isoforms with 54-nt exons11, which are likely to be involved in heterodimer 
formation with ACTR5. U2AF35 depletion altered expression of multiple INO80 components, including ACTR5, 
ACTL6A and RUVL2B11. Many INO80 subunits are also preferentially located in telomeres30. U2AF was required 
for full inclusion of TERF1 exon 7 in the mRNA (Fig. S6a), thus controlling the relative abundance of TRF1 (exon 
7+ )/PIN2 (exon 7− ) isoforms, important components of the telomeres-protecting shelterin complex. Exon 7 
encodes multiple phosphorylated serine residues and both isoforms can heterodimerize through the dimerization 
www.nature.com/scientificreports/
8Scientific RepoRts | 6:18741 | DOI: 10.1038/srep18741
domain31. TRF1 binding to telomeres is also promoted by ATM inhibition whereas ATM-mediated phosphoryla-
tion impairs TRF1 interaction with telomeric DNA32. TRF1 association with telomeres is also negatively regulated 
by RAD5032. TRF1-interacting TIF2, another shelterin protein localized in nuclear matrix, exists in at least two 
isoforms produced by alternative splicing, termed TIN2S and TIN2L33. TIN2L contains an extra NM binding 
domain and associates more strongly with the nuclear matrix than TIF2S¸which is encoded by a transcript with 
retained 3′ introns that form a long 3′ untranslated region33. This mRNA isoform was repressed by U2AF (Fig. S6b).
Figure 5. Exon-centric regulation of ATM signalling. (a) U2AF-regulated gene- and exon-level expression 
changes in MRN-ATM-CHEK2-CDC25-cdc2/cyclin B pathway (left panel). Log2fold- and q-values63 are 
shown in parentheses. Exon usage of CHEK2 and CDC25A genes is shown by RNA-Seq browser shots; PCR 
validation gels are in the right panels. CHEK2 exon 9 is a NMD switch exon; exon 11 encodes a portion of the 
kinase domain. Full spectrum of U2AF-mediated expression changes in the ATM signalling pathway is shown 
in Fig. S2; examples of the U2AF-mediated splicing regulation are in Figs S3–S6. (b) Impaired ATM signalling 
in U2AF35 depleted cells following IR. HEK293 cells were (mock)depleted of U2AF35 and subjected to IR 
(10 Gy) 48 hrs later. Expression was examined by immunoblotting at the indicated time points. Antibodies are 
shown to the right. CHEK2 exon 9 skipping levels are at the bottom; their measurements in control (U2AF35+ ) 
and depleted cells (U2AF35− ) are in panel (c). (d) CHEK2 exon 9 inclusion in UPF1 depleted cells. Final 
concentration of the UPF1 siRNA (Table S1) was 12.5, 25, 50, and 100 nM. (e) Repression of CHEK2 exon 9 by 
SSO reduced CHEK2 levels and promoted NSE inclusion. Final concentration of SSO targeting CHEK2 exon 9 
was 3, 10 and 30 nM. (f) CHEK2 exon 9 inclusion upon transfection of HEK293 cells with the indicated SSOs. 
(g) A lack of SF3B1 induced CHEK2 exon 9 skipping but did not alter NSE activation. Final concentration of 
each siRNA targeting SF3B1 was 20 nM.
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Collectively, these results show that the MRN/ATM-CHEK2-CDC25-cdc2/cyclin B axis is at the centre of the 
U2AF(35)-mediated control of DDR, although the U2AF regulation extends into additional ATM substrates, 
mainly involved in chromatin modification and telomere activity.
U2AF preferentially controls RNA processing of transcripts involved in leukemia-associated 
fusions. CHEK2 phosphorylates PML (Promyelocytic Leukemia) and appears to require PML for subsequent 
autophosphorylation34. Depletion of U2AF35 promoted the use of proximal alternative polyadenylation site of 
PML, leading to the upregulation of the shortest PML isoform, which lacks the last exon coding for the nuclear 
export signal (Fig. S7a). The long and short PML isoforms have distinct functions; for example, nuclear PML 
isoforms, but not the cytoplasmic isoform, are positive regulators of IFNγ signalling35. The C-terminus of the 
longest isoform specifically interacts with AML1 to enhance AML1-mediated transcription36, suggesting that 
U2AF deficiency could impair PML-AML1 interactions. PML also binds PIN1 and this interaction promotes 
PML degradation in a phosphorylation-dependent manner37. U2AF depletion increased a PIN1 NMD exon (Fig. 
S4b), potentially limiting expression of this abundant peptidyl-prolyl isomerise, which interacts with many phos-
phoproteins to regulate mitosis, including phosphorylated CDC2538. Apart from PML, U2AF35 depletion upreg-
ulated other RARA partners, including NPM1 (Fig. S7b). This event was associated with promotion of a proximal 
polyadenylation site and increased the abundance of shorter transcripts. An alternatively spliced exon of BCOR, 
a BCL6 corepressor that forms BCOR-RARA fusions39 and interacts with several histone deacetylases to increase 
BCL6 transcriptional repression40, was also downregulated (Fig. S7c).
Interestingly, the overlap between U2AF35-sensitive genes/exons and 1,187 genes involved in cancer-associated 
gene fusions41 and 300 genes involved in recurrent chromosome translocations42 was greater than expected, with 
more significant P values for genes with differentially used exons than those implicated by the Cufflinks algorithm 
(Table 1). Similarly, sharing of genes frequently mutated in the myelodysplastic syndrome43 and genes differen-
tially expressed upon U2AF35 depletion11 was significantly higher than expected (P < 0.01, hypergeometric test). 
Thus, RNA processing of transcripts involved in cancer-associated gene fusions and chromosome translocations 
is preferentially regulated by U2AF.
To test the function of cancer-associated U2AF1 mutations in NSE splicing, we performed reconstitution 
experiments with wild-type and mutated U2AF35 constructs that were cotransfected with the C minigene into 
cells (mock)-depleted of U2AF35 (Fig. 6). NSE activation was repressed by either U2AF35 isoform to a similar 
extent, as well as U2AF35a containing cancer-associated substitutions of S34 in the zinc finger 1 domain, the most 
frequently mutated U2AF35 residue in cancer7. In contrast, only a partial rescue was achieved by substitutions 









ChimerDB 2.0 41 1,187 66 P < 0.00004/1.7 204 P < 0.02/1.1
Genes involved in recurrent 
structural abnormalities in cancer 42 300 19 P < 0.006/1.9 56 P < 0.05/1.2
Table 1.  U2AF35-dependent transcripts are more common than expected among genes involved in 
cancer-associated gene fusions and recurrent chromosomal translocations. 1Gene lists were downloaded on 
2 April 2014. 2Exon- and gene-level analysis of RNA-Seq data was carried out for 23,263 genes using DEXSeq 
and Cufflinks, respectively, as described in detail11. 3Number of overlapping genes divided by the expected 
number of overlapping genes drawn from two independent groups. A representation factor > 1 indicates a 
greater overlap than expected of two independent groups, the value < 1 indicates less overlap than expected. 
P-values were derived by hypergeometric tests.
Figure 6. Rescue of NSE repression by cancer-associated mutations in U2AF35. Rescue of U2AF(35)-
dependent NSE splicing of the C minigene by zinc finger 1 and 2 substitutions in U2AF35 (upper panel). All 
substitutions were made in the U2AF1a construct (35a)11. Cancer-associated mutations (bottom) are boxed; 
splice products are to the right. Error bars are SDs of 2 transfections. Immunoblot with U2AF35 and GFP 
antibodies is shown in the lower panel; ex, exogenous; en, endogenous U2AF35.
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of Q157 in the second zinc finger domain where these mutations are less frequent. Other S34 mutations failed to 
fully reconstitute the defect, including S34T and substitutions with small amino acids, although a large residue at 
this position (S34R) was efficient, suggesting that the size of this residue is critical for ligand binding. Thus, the 
identity of the residue at position 34 of U2AF35 was important for NSE recognition.
Finally, we detected a low degree of NSE activation in diverse human tissues, both in hexamer-primed samples 
and polyadenylated transcripts (Fig. S8a). The proportion of NSE-containing RNAs was on average higher in leu-
kemic cells than in normal cells, with some samples exhibiting very high levels (Fig. S8b,c), potentially contributing 
to reduced ATM expression in cancer cells. We also examined NSE inclusion in polyadenylated RNAs extracted 
from a panel of lymphoblastoid cell lines exposed to cold and heat shock at the indicated temperatures prior to lysis 
(Fig. S8d,e). Interestingly, NSE was activated to a minor extent by exposing cells to 42 °C but not at subphysiological 
temperatures (Fig. S8d), suggesting that markedly higher NSE inclusion levels in malignant cells are unlikely to 
be explained by a cold shock encountered during storage of patients’ samples. Since proteomic profiling of Jurkat 
cells exposed to a heat stress at 43 °C revealed diminished expression of several proteins including U2AF35a44, 
these results further support U2AF35 as a specific NSE repressor.
Discussion
Here we have identified an alternative splicing-coupled NMD switch exon critical for ATM expression (Figs 1 and 3) 
and examined its importance in cancer risk (Fig. 2, Fig. 6 and S8). We have also shown how inclusion of this exon 
in mature transcripts is influenced by intronic haplotypes and RNA-binding proteins involved in 3′ ss selection 
(Figs 2 and 4h). Finally, we have identified SSOs that modulate activation of this exon by targeting its regulatory 
sequences and proposed a novel antisense strategy for modifying gene expression. These results significantly expand 
currently known links between RNA processing and DDR pathways (Fig. 5 and S2).
U2AF-repressed exons have a distinct 3′ ss organization and response to U2AF-related proteins as compared to 
U2AF-activated exons11, suggesting that the NSE repression involves direct RNA binding. This is supported by the 
observed NSE activation on exogenous transcripts that do not undergo NMD and by the SSO-induced NSE block-
age (Figs 2 and 4). NSE lacks AG dinucleotides between the predicted BPS and 3′ ss, its AG exclusion zone is longer 
than the average and has an unusual stretch of 5 conserved guanines upstream of the BPS, which may contribute 
to stable secondary structures across 3′ ss that might be required for the inhibition. The adenine-rich 3′ portions 
of both NSE and PE are more conserved in evolution than their 5’ parts (Fig. 4a), potentially providing important 
ligand interactions, given the propensity of adenine to occupy unpaired positions in structured RNAs. Although 
direct RNA binding appears to be the simplest explanation for exon repression by U2AF, U2AF35 depletion led 
to downregulation of several proteins involved in NMD (Table S4), which may contribute to NSE activation on 
endogenous transcripts. Physical interactions between U2AF65 and the C-terminus of TRF145 or other components 
of the ATM signalling network46 could also participate in NSE regulation. A challenge ahead will be to gain insight 
into mechanisms of NSE repression in normal and cancer cells where the NSE control appears to be compromised, 
potentially altering ATM expression and DDR in the haplotype-dependent manner (Fig. 2 and S8b,c).
Apart from U2AF1/U2AF2, additional genes involved in 3′ ss selection have been found mutated in cancer7. 
Interestingly, chronic lymphocytic leukemias with SF3B1 mutation were associated with a cryptic 3′ ss activation 
of ATM exon 46, leading to ATM truncation47. Splicing of an EZH2 exon as a result of cancer-associated SRSF2 
mutation was implicated in impaired hematopoietic differentiation48 and the same NMD exon was upregulated 
also in cells lacking U2AF35 (Fig. S5d). Whether these exons are targets of a common 3′ ss recognition pathway 
underlying leukemogenesis remains to be established.
Because NSE activation may restrict ATM expression both in normal and cancer cells (Figs 1,2, and S8) and 
ATM is a limiting factor in the DDR pathway22, cytosine at rs609261 may confer a relative ATM deficiency also 
in the germline. ATM kinase activity appears to be a good predictor of A-T severity, however, the diversity of A-T 
alleles does not fully account for the spectrum of clinical symptoms, arguing for the role of additional factors49. 
Our results suggest that genes involved in NSE activation and natural variants modulating NSE inclusion (Figs 1, 
2c–f and 4h) could modify the phenotypic complexity of A-T and also A-T heterozygotes who lack overt clinical 
features but may display increased radiosensitivity and cancer risk50, ie. phenotypes influenced by the critical 
U2AF-regulated pathway in the ATM signalling network (Fig. S2). Although the SSO-induced repression of endo-
geneous NSE transcripts was observed also in untreated cells (Fig. 3b) and NMD transcripts with the relative 
abundance as low as ~1% can dramatically contribute to the mRNA consumption51, it remains to be tested if their 
reduction can lead to a sustained increase of ATM protein levels. This approach may have a potential to alleviate 
phenotypic consequences of leaky A-T alleles in a mutation-independent manner, particularly in patients carrying 
the C allele at rs609261.
Our results also show that NSE activation is on average more efficient in Caucasians than in Asian populations 
as a result of the higher frequency of the C allele at rs609261 in the former (Fig. 2). This differential NSE control 
may potentially contribute to persistently lower mortality rates for common malignancies in Asian populations 
than in Caucasians52,53. rs609261 is only ~35 kb downstream of rs2235006, which is located in a region of minimal 
meiotic recombination54 and was associated with a high risk (OR 11.2) of chronic lymphocytic leukemia55. This 
study genotyped 1467 coding nonsynonymous SNPs in 865 candidate genes and implicated variants in genes 
encoding the ATM-BRCA2-CHEK2 DDR axis as the most significant risk pathway. Asian cancer patients were also 
found to exhibit a lower prevalence of some gene fusions than Caucasians56, potentially reflecting their capacity 
to respond to DSBs.
Our study also highlights current limitations of incomplete transcript annotation and the importance of exam-
ining cryptic exons in RNA-Seq data. Although RNA-Seq is a powerful tool to examine global transcriptome, 
rigorous standards that correctly evaluate biological and statistical significance of the observed alterations in RNA 
processing are yet to be implemented. Given a high stringency of the default DEXSeq algorithm11,57, we cannot 
exclude the existence of additional biologically important RNA processing events regulated by U2AF. For example, 
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promotion of a proximal polyadenylation site in CHEK1 in depleted cells coupled with upregulation of 24-nt and 
27-nt exons in CLASP1, events observed in genomic browsers, would implicate the ATM apoptotic pathway. This 
pathway is of particular interest in the myelodysplastic syndrome where myeloid progenitors show susceptibility 
to the programme cell death, mutations in 3′ ss recognition genes are particularly frequent7, and deregulation of 
genes involved in ATM signalling is associated with more advanced clinical stages58. Interestingly, U2AF1 mutations 
were found to be more frequent in later stages and were associated with shorter survival59.
Finally, our work demonstrates efficient repression of a critical NMD switch exon in ATM by SSOs that target 
regulatory motifs of competing pseudoexons and are capable of increasing ATM protein levels (Figs 3a–d, 4 and 
S1). The proposed strategy may be combined with genome editing such as CRISPR-Cas9 to alter splicing regula-
tory motifs or protein binding sites in introns and should also help us to find efficient intronic SSOs with desired 
outcomes for RNA processing. The search for such SSOs is more challenging than for those targeting human exons. 
For example, most SSOs systematically covering SMN2 exon 7 stimulated exon skipping, which is required for 
antisense therapy of spinal muscular atrophy, however, ~20% increased exon inclusion60. Conversely, stimulation 
of intron splicing was found only for ~10% of SSOs targeting INS intron 1 while the majority failed to show this 
effect61. The versatility of intronic or exonic SSOs to modulate splicing in either direction exploits a much higher 
information content of auxiliary splicing sequences in humans as compared to lower organisms. Future SSO design 
strategies should be therefore greatly facilitated by global pre-mRNA folding and RNA crosslinking and immu-
noprecipitation studies. For example, unlike the SSO that efficiently blocked the NSE 3′ ss (SSO-NSE3, Fig. 3a,b), 
a partially overlapping morpholino extending only 7-nt into NSE failed to repress the same 3′ ss to rescue splicing 
of mutation IVS28-159A> G62, despite targeting U2AF binding sites (Fig. 4a). This suggests that the morpholino 
blocked access to structures or motifs that are not responsible for exon activation, but exon repression, in agreement 
with our finding (Fig. 1a–c). Thus, administration of antisense-based RNA processing activators or inhibitors that 
target or avoid binding sites of splicing factors in introns could be exploited therapeutically to shape beneficial or 
detrimental consequences of NMD in cancer cells.
Methods
Plasmid constructs. ATM minigenes were prepared by cloning ~0.9-kb amplicons into XhoI/XbaI sites of 
the U2AF1 construct described earlier11. Cloning primers are shown in Table S1. Full inserts were sequenced 
to confirm the identity of intended changes and exclude undesired mutations. The PUF60 expression vector 
was described previously11. The hnRNP A1 construct was a generous gift of Gideon Dreyfuss (University of 
Pennsylvania).
Cell cultures and transfections. Cell cultures were maintained in standard conditions in DMEM supple-
mented with 10% (v/v) bovine calf serum (LifeTechnologies). Depletion of U2AF subunits and U2AF35 isoforms 
with small interfering RNAs (siRNAs) and splice-switching oligonucleotides (SSOs), were carried out following 
a time course experiment that established depletion levels of each isoform, as described11. All oligo(ribo)nucle-
otides are listed in Table S1. Transfections were carried out in 6- or 12-well plates using jetPRIME (Polyplus) 
according to manufacturer’s recommendations, as described in detail11. The cells were harvested 48 hrs after the 
second hit, except for those exposed to IR, which received a single hit. For SF3B1 depletion, HEK293 cells were 
exposed to a siRNAs mixture (S23850, S23852, S223598, LifeTechnologies) and were harvested 48 hrs later.
RNA-Seq. Analysis of differential exon usage was performed using DEXSeq (v. 1.12.1)57, based on q-values 
less than 0.05, as described in detail11. Differential gene and isoform expression between replicated sample sets 
was analyzed with Cufflinks (v. 2.1.1)63, which normalizes the reads using a fragments per kilobase of exon model 
per million reads measure. Selection of significantly differentially expressed genes was made on the basis of 
FDR-adjusted P-values (q < 0.05). Cells, RNA extraction and library preparation was as described previously11.
NSE expression in human tissues and cell lines. The FirstChoice human total RNA survey panel con-
taining total RNA samples from 19 different tissues was purchased from LifeTechnologies. Each tissue sample 
contained a pool of RNAs from different donors. Lymphoblastoid cell lines exposed to cold and heat shock were 
described previously64. Total RNA samples were reverse transcribed with the Moloney murine leukemia virus 
reverse transcriptase (Promega) and random hexamer or oligo-d(T) primers. cDNA samples were amplified 
using primers shown in Table S1. Total RNA extracted from leukocytes from bone marrow samples of randomly 
selected patients with acute myeloid leukemia or chronic myelomonocytic leukemia was reverse transcribed with 
random hexamer primers. The study was approved by the National Research Ethics Service (UK) Committee 
South West.
Splice-switching oligonucleotides. SSOs were designed to maximize interactions with single-stranded 
regions21 and avoid secondary structures predicted by Mfold65. All SSOs were purchased from Eurofins, diluted 
in water and their aliquots were stored at − 80 °C. Their sequences are in Table S1. All transfections were carried 
out with jetPRIME (Polyplus) according to manufacturer’s recommendations.
Exposure of cell cultures to ionizing irradiation (IR). (Mock)-depleted HEK293 cells were exposed to 
IR 48 hours after the first hit using a Gulmay Medical (X-Strahl) D3225 Orthovoltage X-ray system at a dose-rate 
of 0.63 Gy min−1 at room temperature. The actual dose rate was monitored by a constancy meter. Cells were har-
vested as indicated in figure legends.
Immunoblotting. Preparation of cell lysates and immunoblotting was carried out as described11. Antibodies 
against ATM (D2E2), ATM-pS1981 (D6H9), CHEK2 (D9C6) and CHEK2pThr68 (C13C1) were purchased from 
the Cell Signaling Technology, Inc. RBM39 (CAPERα) antibodies were purchased from Thermo Fisher Scientific 
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(PA5-31103). Antibodies detecting X-press tag, U2AF35, U2AF65, and tubulin were as described previously11. 
SF3B1 and FUBP1 immunoblotting was performed with anti-SAP155 (D138-3, MBL) and anti-FBP (GTX104579, 
GeneTex) antibodies, respectively. ATM signal intensity was measured by densitometry using ChemiDoc XRS 
(BioRad) and serial dilutions of pooled lysates on SDS-PAGE to determine the linear dynamic range of protein 
loading. Densitometric signal was normalized to total blot-transferred protein (Fig. S1a,b) since U2AF35 deple-
tion alters expression of hundreds of exons, many in housekeeping genes11.
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